shutterstock_1532109092_sundry_photography

Sundry Photography / Shutterstock.com

7 October 2021Medtech

Federal Circuit hands victory to Snyders over heart valve patent

The US Court of Appeals for the Federal Circuit has held that claims of a patent covering an artificial heart valve were erroneously held to be unpatentable by the US Patent Trial and Appeal Board (PTAB), in a blow to a medical device company owned by Abbott Laboratories.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

More on this story

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

More on this story

Snyders revives patent claims against St Jude Medical

25 March 2021 Snyders Heart Valve has been successful in reviving patent claims in an on-going dispute against St Jude Medical.

Federal Circuit resuscitates Snyder’s heart valve patent

16 October 2020 A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent